Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Veramark Technologies, Inc. (NASDAQ: VERA) | Delayed: 27.99 -1.06 (3.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $29.05 | 52 Week High | $1.18 | |||
| Open | $28.75 | 52 Week Low | $0.36 | |||
| Day High | $29.44 | P/E | 466.50 | |||
| Day Low | $27.46 | EPS | $0.06 | |||
| Volume | 1,981,932 | |||||
